-2-

The fo lowing is a complete listing of all claims in the application, with an indication of the status of e: ch:

Listing of cla ms:

1. (Previously presented) A compound of the general formula

where

m is a: . integer from 0 to 5;

n is ar integer from 0 to 5;

R is C to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH_2X^1, when $X^1 = H$, Cl, Br, I or F;

R_1 is I ., C_1 to C_7 alkyl, phenyl, or substituted phenyl;

R_2, R_3 R_4 and R_5 are H or C_1 to C_7 alkyl, and R_1, R_2, R_3, R_4 and R_5 may be the same or different; and

X is CH_2 or a saturated or unsaturated C_2 carbon chain.

−3−

2. (Previously presented) A compound of formula

3. (Previously presented) A compound of formula

4. (Previously presented) A compound of formula

-4-

5. (Previously presented) A compound of formula

6. (Previously presented) A compound of formula

7. (Currently amended) A method of treatment of a condition or disorders related to cannabinoid-regulated sys ems in a patient in need thereof, wherein if said compound is an agonist of a CB1 receptor ther said condition is selected from the group consisting of acute pain; chronic pain; inflammatio ; loss of appetite, convulsions, spasticity associated with multiple sclerosis; convulsions; epilepsy; and nausea and vomiting; and wherein if said compound is a silent antagonist o a CB1 receptor then said condition is selected from the group consisting of obesity; impaired cor nition, and alcohol, tobacco, cocaine or marijuana dependence, comp rising the step of

-5-

administering to said patient a quantity of a compound of formula

where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH_2X^1, where $X^1 = H$, Cl, Br, I or F;

R_1 is H, C_1 to C_7 alkyl, phenyl, or substituted phenyl;

R_2, R_3 R_4 and R_5 are H or C_1 to C_7 alkyl, and R_1, R_2, R_3, R_4 and R_5 may be the same or different; and

X is CH_2 or a saturated or unsaturated C_2 carbon chain,

in a quantity sufficient to ameliorate symptoms of said condition or disorder.

8-9. (Cancel)

10. (Currently amended) A method for treating pain in a patient comprising administering to said patient an effective dose of an agonist of a CB1 cannabinoid receptor wherein said agonist includes a sulfonamide moiety, and wherein said agonist has the chemical formula

-6-

where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C_1 to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH_2X^1, where X^1 = H, Cl, Br, I or F;

R_1 is H, C_1 to C_7 alkyl, phenyl, or substituted phenyl;

R_2, R_3, R_4 and R_5 are H or C_1 to C_7 alkyl, and R_1, R_2, R_3, R_4 and R_5 may be the same or different; and

X is CH_2 or a saturated or unsaturated C_2 carbon chain, with the proviso that if R is CH_3 then X must be CH_2 or a saturated C_2 carbon chain.

1

11. (Cancel)

12. (Previously presented) The method of claim 10 wherein said agonist is selected from the group consisting of

-7-

and

13. (Currently amended) A method for treating nausea in a patient comprising administering to said patient ar effective dose of an agonist of a CB1 cannabinoid receptor wherein said agonist includes a sulionamide moiety, and wherein said agonist has the chemical formula

where

      m is an integer from 0 to 5;

      n is an integer from 0 to 5;

-8-

R is C_1 to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH_2X^1, where X^1 = H, Cl, Br, I or F;

R_1 is F, C_1 to C_7 alkyl, phenyl, or substituted phenyl;

R_2, R_3, R_4 and R_5 are H or C_1 to C_7 alkyl, and R_1, R_2, R_3, R_4 and R_5 may be the same or different; and

X is C_{12} or a saturated or unsaturated C_2 carbon chain, with the proviso that if R is CH_3 then X must be CH_2 or a saturated C_2 carbon chain.

14. (Cancel)

15. (Previously presented) The method of claim 13, wherein said agonist is selected from the group consisting of


and

16. (Cancel)

-9-

17. (Currently amended) A method for treating obesity in a patient comprising administering to said patient an effective dose of a silent antagonist of a CB1 cannabinoid receptor wherein said silent antagonist includes a sulfonamide moiety, <u>wherein said silent antagonist is</u>

18-20. (Cancel)

-9-